KZIA
Kazia Therapeutics Ltd
9.40$
+0.9%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 56.6% | 96.8% | 96.0% | 54.2% | 32.9% | 35.6% | 46.2% | 50.6% | 26.3% | 38.4% | 28.5% | 81.4% | |
| 53.7% | 96.2% | 94.2% | 40.3% | 21.1% | 25.7% | 38.0% | 47.5% | 20.5% | 18.7% | 7.7% | 71.7% | |
| 53.7% | 96.2% | 94.2% | 40.3% | 21.1% | 25.8% | 38.0% | 47.5% | 20.5% | 18.7% | 7.7% | 71.7% | |
| 1.3% | 0.0% | 0.3% | 0.0% | 0.0% | 7.4% | 0.0% | 0.1% | 0.1% | 0.4% | 0.6% | 1.5% | |
| 0.0% | 0.0% | 1.2% | 0.0% | 0.0% | -7.3% | 0.0% | -0.1% | – | -13.5% | – | – | |
| 0.2% | 0.1% | 1.7% | 1.4% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 42.1% | 3.0% | 2.3% | 44.3% | 51.7% | 63.7% | 53.8% | 37.9% | 53.3% | 61.5% | 71.3% | 17.9% | |
| 69.7% | 3.9% | 4.5% | 29.4% | 31.7% | 33.1% | 38.8% | 34.8% | 49.1% | 57.1% | 146.4% | 237.0% | |
| 69.7% | 3.9% | 4.0% | 15.0% | 13.8% | 10.4% | 22.0% | 14.3% | 18.7% | 26.9% | 119.5% | 231.9% | |
| 58.1% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | – | – | 5.1% | 6.4% | 2.9% | 6.5% | |
| 1.7% | 1.7% | 1.4% | 3.5% | 5.0% | 5.0% | 7.3% | 3.3% | 4.2% | 3.1% | 21.1% | 93.1% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | |
| 32.4% | 96.8% | 95.5% | 70.6% | 68.3% | 67.0% | 61.2% | 65.2% | 50.9% | 42.9% | -46.4% | -137.0% | |
| -3,032.9% | -321.7% | -451.9% | -476.1% | -52.0% | -117.8% | -156.9% | -76.1% | -191.2% | -317.2% | -533.4% | -2,224.5% | |
| 0.7% | 0.1% | 0.3% | 0.3% | 0.4% | 0.6% | 0.7% | 0.4% | 0.7% | 1.3% | 2.2% | 18.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.